Because SGLT2 inhibitors work by an insulin-independent mechanism, this class of compounds may be of benefit as adjunctive therapy in patients whose pancreatic function is diminished or in patients who have insulin resistance. This evidence concerns the gene SLC5A2 and Insulin resistance.